Loading
A phase 2 trial of Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide and Flotufolastat F-18 in Prostate cancer, run by Baptist Health South Florida, now recruiting.
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT is a phase 2 interventional study registered as NCT07455903 by Baptist Health South Florida, with 50 participants planned, started 2026-07-29 and due to reach its primary completion in 2030-02. Interventions recorded: Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy. Conditions recorded: Prostate Cancer, Localized Prostate Carcinoma.
Linked to the drug Flotufolastat F-18 because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Relugolix, Degarelix, Triptorelin, Bicalutamide and the tag pipeline.
Shares Relugolix, Degarelix, Triptorelin, Leuprolide (leuprorelin) and GnRH agonists and the tag pipeline.
Shares Degarelix, Triptorelin, Bicalutamide, Leuprolide (leuprorelin) and GnRH agonists and the tag pipeline.
Shares Degarelix, Triptorelin, Bicalutamide, Prostate cancer and the tag pipeline.
Shares Degarelix, Bicalutamide, Prostate cancer and the tag pipeline.
Shares Degarelix, Bicalutamide, Prostate cancer and the tag pipeline.
Shares Flotufolastat F-18, Prostate cancer and the tag pipeline.
Shares Flotufolastat F-18, Prostate cancer and the tag pipeline.